Gene

NFIB

nuclear factor I B

Curated evidence

Clinical evidence (3)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
NFIB Fusion3
Linsitinib	DOID:0080202UNRESOLVED	Predictive	D	Supports Sensitivity Response	2	submitted	EID12164 In a study of oncogenic signalling pathways, tumours and cultured cells from 15 patients with MYB-NFIB translocation-positive adenoid cystic carcinoma (ACC) were analyzed. Treatment with linsitinib, a… (full text at CIViC) PMID 28954282 · Andersson et al., 2017 · Open in CIViC	civic
Crizotinib + Gefitinib + LinsitinibCombination	DOID:0080202UNRESOLVED	Predictive	B	Supports Sensitivity Response	2	submitted	EID12167 Treatment of ACC cells with a combination of linsitinib, crizotinib, and gefitinib resulted in synergistic inhibition of cell proliferation (p = 0.004). This combination also significantly downregulat…

Cohorts

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

gdcObserved2 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Skin Cutaneous Melanoma TCGA-SKCM	Cutaneous Melanoma	Ssm

Literature

Data not yet available

No publication linked to this gene yet.